Cognition and Imaging With Tigertriever for Stroke
This observational study, called the COGNITIVE Study, is looking at people who have had a stroke caused by a large vessel occlusion (LVO). Researchers want to see if using a device called Tigertriever to successfully restore blood flow (successful reperfusion) is linked to better thinking and memory skills (cognitive benefit) 180 days after treatment. You might be able to join if you are between 18 and 75 years old, had an LVO stroke, and the Tigertriever was used as the first treatment. The study is currently unclear on its status and aims to include 424 participants.
- Study design
- This is an observational study, meaning researchers will observe participants without assigning specific treatments. It plans to include 424 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will assess cognitive benefit 180 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cognition and Imaging With Tigertriever
At a glance
Conditions
NCT05531461
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Corewell Health Research Institute
Grand Rapids, Michiganstudy coordinator listed
Recruiting
University of California
Los Angeles, Californiastudy coordinator listed
Recruiting
Westchester Medical Center
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Association between successful reperfusion* and cognitive benefit**180 days post treatment
\*successful reperfusion is defined as eTICI ≥2b50 with the Tigertriever device. * Cognitive benefit is defined as change in Montreal Cognitive Assessment (MoCA) of 1.5 Standard Deviations (SD) from 4 days post treatment (or discharge if earlier) and 180 days post treatment; or MoCA ≥26 at 180 days post treatment.